NeoGenomics, Inc. (NEO)

NeoGenomics' stock has increased by 72.04% in the past six months, but declined by 31.71% over the past year. Key events include a Q3 2025 earnings beat, a preliminary Q4 and full-year 2025 revenue announcement, a CFO transition, and a patent dispute resolution. As of January 12, 2026, NeoGenomics has an average rating of "Hold" from analysts, with a consensus price target of $12.00. On January 12, 2026, shares fell 7.4%, trading as low as $12.72 and closing at $12.1880.

The demand for NeoGenomics' clinical testing services generally experiences modest declines during the summer vacation season, year-end holiday periods, and other major holidays. Testing volumes can decrease due to extreme adverse weather conditions. Demand for pharmaceutical development services can be unpredictable due to funding uncertainty and changing drug development timelines.

NeoGenomics, Inc. is an American clinical laboratory, pharma services, and information services company specializing in cancer genetics diagnostic testing, operating within the Healthcare sector and the Medical Diagnostics & Research industry. The company provides oncology-focused testing services to various organizations. Its services include molecular testing, cytogenetics, FISH, flow cytometry, IHC, anatomic pathology, liquid biopsy tests, MRD testing, pharma services, and oncology data solutions.

NeoGenomics is headquartered in Fort Myers, Florida, and operates a network of CAP-accredited and CLIA-certified laboratories across the United States and internationally. In the United States, laboratories are located in Fort Myers, Tampa, Aliso Viejo, Carlsbad, San Diego (La Jolla), Fresno, Research Triangle Park, Houston, Atlanta, Nashville, and Phoenix. Internationally, NeoGenomics has laboratories in Rolle, Switzerland; Singapore; Cambridge, United Kingdom; and Suzhou, China.

NeoGenomics aims to be the "cancer testing 'partner of choice'" and emphasizes its commitment to quality, integrity, accountability, teamwork, and innovation. In March 2024, NeoGenomics released its inaugural ESG Report, highlighting progress in building a sustainable, diverse, and equitable company. A patent dispute with Natera concerning NeoGenomics' RaDaR assay was resolved when Natera voluntarily dismissed its appeal in December 2025, following a ruling that favored NeoGenomics.

NeoGenomics has a diverse ownership structure, with institutional investors holding a significant portion of the company's stock. Approximately 81.73% of the company's stock is owned by Institutional Investors, 1.20% by Insiders, and 17.07% by Public Companies and Individual Investors. Major institutional owners include BlackRock, Inc. and Vanguard Group Inc. Notable individual owners include Electric Co General, Peter M. Peterson, Steven C. Jones, and Michael T. Dent.